论文

SCOPE-AD:基于能量模型的阿尔茨海默病诊断智能体

SCOPE-AD: Sequential cost-aware ordinal-belief planning with energy-based models for diagnostic agents

精选理由

SCOPE-AD智能体通过选择性测试获取,在保持高诊断准确率的同时大幅降低医疗成本。

SCOPE-AD是一种用于阿尔茨海默病诊断的智能体系统,能够在认知正常、轻度认知障碍和阿尔茨海默病三种状态间进行分类。该系统在ADNI数据集上实现了77.70%的Macro-F1分数,平均获取成本为50.46美元,比最强基线高出9.34个百分点。全模态评估仅将Macro-F1提高1.89个百分点,但获取成本增加了116.7倍。

原文 · arXiv cs.AI

SCOPE-AD: Sequential cost-aware ordinal-belief planning with energy-based models for diagnostic agents

Alzheimer's disease (AD) diagnosis requires sequential evidence acquisition under heterogeneous test costs and patient burden. Fixed-modality predictors do not jointly decide which test to acquire or when the available evidence is sufficient for diagnosis. We propose SCOPE-AD (Sequential Cost-Aware Ordinal-Belief Planning with Energy-Based Models for Diagnostic Agents) for cost-aware classification of cognitively normal (CN), mild cognitive impairment (MCI), and AD cases. A mask-aware ordinal model represents uncertainty along the ordered CN--MCI--AD continuum. Retrospective training records provide sampled Bellman targets for an energy-based teacher, whose action distributions are distilled into a Qwen policy. At deployment, the agent selects acquisition or diagnosis actions under availability and budget constraints without access to unacquired values. After each acquisition, the evidence and ordinal belief are updated before the next decision. On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46, exceeding the strongest evaluated baseline by 9.34 percentage points. Full-modality evaluation raises Macro-F1 by only 1.89 points while increasing acquisition cost by 116.7 times. These results support selective acquisition for cost-effective diagnosis.